Medinol continued its introduction of its novel stent solutions during the 2015 Transcatheter Cardiovascular Therapeutics (TCT) meeting in San Francisco.
The key attributes of the Medinol NIRxcell CoCr coronary stent system and the Medinol eDES coronary stent system were discussed by a physician panel during the satellite symposium.
Physician faculty included David E Kandzari, Piedmont Heart Institute, USA, Jim Zidar, North Carolina Heart and Vascular, USA, Rajiv Jauhar, North Shore University Medical Center, USA, Peter Smits, Maasstad Ziekenhuis, Rotterdam, the Netherlands and Shmuel Banai, The Tel Aviv Sourasky Medical Center, Tel Aviv, Israel. Discussion highlighted key product features and emphasised the unique design of the BIONICS/NIREUS clinical trials that have recently completed enrolment. Kandzari comments, “The delivery system is unlike in any other product on the market,” and that Medinol’s approach to trial design “was entirely unlike any other pivotal trial as it included a ’more comers’ patient population.”
Medinol US recently opened their commercial business in Parsippany, USA followed by the launch of NIRxcell CoCr Stent System. Matt Donnelly, US general manager, comments, “Our goal is to provide optimal solutions for patient treatments through innovative product designs, novel and efficient manufacturing processes and robust clinical data. We believe that this is a winning combination to drive a product portfolio that will offer value to patients, physicians and healthcare facilities.”